Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Loans and Notes Receivables (2016 - 2018)

Ligand Pharmaceuticals' Loans and Notes Receivables history spans 4 years, with the latest figure at $3.9 million for Q1 2018.

  • For Q1 2018, Loans and Notes Receivables changed N/A year-over-year to $3.9 million; the TTM value through Mar 2018 reached $3.9 million, changed N/A, while the annual FY2017 figure was $3.9 million, 20.89% up from the prior year.
  • Loans and Notes Receivables for Q1 2018 was $3.9 million at Ligand Pharmaceuticals, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Loans and Notes Receivables topped out at $5.5 million in Q2 2015 and bottomed at $3.0 million in Q3 2017.
  • The 4-year median for Loans and Notes Receivables is $3.9 million (2017), against an average of $4.1 million.
  • The largest annual shift saw Loans and Notes Receivables tumbled 42.18% in 2016 before it grew 20.89% in 2017.
  • A 4-year view of Loans and Notes Receivables shows it stood at $4.8 million in 2015, then crashed by 32.94% to $3.2 million in 2016, then increased by 20.89% to $3.9 million in 2017, then changed by 0.0% to $3.9 million in 2018.
  • Per Business Quant, the three most recent readings for LGND's Loans and Notes Receivables are $3.9 million (Q1 2018), $3.9 million (Q4 2017), and $3.0 million (Q3 2017).